Fortis Healthcare Limited is navigating a leadership transition after announcing the resignation of its Chief Growth & Innovation Officer, Dr. Ritu Garg, effective at close of business on October 31, 2026. In a move that underscores the ongoing evolution of the company’s growth ambitions, Garg has resigned to pursue a professional opportunity outside the organization, marking the departure of a senior executive who has been at the helm of Fortis’ growth and innovation mandate.
Garg’s exit, communicated through Fortis’ official channels, reflects a parting common in dynamic healthcare businesses where growth strategies are continually refreshed to meet changing market realities. In her resignation letter, Garg extended gratitude to the Board and Management for the support and cooperation she received during her tenure, and she wished Fortis every success with its future plans and ambitions. The company has not yet detailed the next steps for filling the role, signaling a period of transition as Fortis considers how to maintain momentum in its growth and innovation agenda.
As Fortis charts this transition, the leadership question turns to how the organization will sustain its momentum in Growth & Innovation. The market will be watching to see how Fortis maintains continuity in its execution while potentially redefining the function’s leadership to align with its future strategy. In the meantime, Fortis continues to position itself as a patient-centric platform exploring new growth avenues and innovative care delivery, even as it delegates ongoing responsibilities to its executive team and broader leadership network.